title: Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children.
abstract: Among Tanzanian children living in an area of intense and perennial malaria transmission, prevalence of naturally acquired IgG antibodies that recognize SPf66, NANP, p190 and a 19 kDa fragment of the merozoite surface protein-1 (MSP-1) is high and increases with age. This possibly reflects the high level of natural exposure of the children to P. falciparum. The prevalences of IgG antibodies that recognize the three putative merozoite derived sequences contained in the malaria vaccine SPf66 (83.1, 55.1 and 35.1) is low but also show some age dependence. Three doses of the SPf66 vaccine induce a strong IgG antibody response against both the SPf66 construct, NANP and the three individual peptides. Vaccination with SPf66 did not result in an increase of anti19 kDa fragment antibodies. This reflects the specificity of the humoral immune response induced by the SPf66 construct. Among vaccinated children, antibody titres against SPf66 decreased over time following the third dose. However, 18 months after the third dose, SPf66 recipients still had significantly higher IgG titres and stimulation indices of peripheral blood mononuclear cells (PBMC) than placebo recipients. Within the vaccine group, there is a trend for increasing anti-SPf66 IgG titre to be associated with decreasing risk of clinical malaria but this was not statistically significant. Results also show the difficulties of establishing whether antibody responses are related to protection in field trials in endemic areas.
authors.affiliation: Unidad de Epidemiologia y Bioestadistica, Hospital Clinic, Barcelona, Spain.
authors.forename: P L
authors.initials: PL
authors.lastname: Alonso
authors.forename: M C
authors.initials: MC
authors.lastname: Lopez
authors.forename: G
authors.initials: G
authors.lastname: Bordmann
authors.forename: T A
authors.initials: TA
authors.lastname: Smith
authors.forename: J J
authors.initials: JJ
authors.lastname: Aponte
authors.forename: N A
authors.initials: NA
authors.lastname: Weiss
authors.forename: H
authors.initials: H
authors.lastname: Urassa
authors.forename: J R
authors.initials: JR
authors.lastname: Armstrong-Schellenberg
authors.forename: A Y
authors.initials: AY
authors.lastname: Kitua
authors.forename: H
authors.initials: H
authors.lastname: Masanja
authors.forename: M C
authors.initials: MC
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Oettli
authors.forename: N
authors.initials: N
authors.lastname: Hurt
authors.forename: R
authors.initials: R
authors.lastname: Hayes
authors.forename: W L
authors.initials: WL
authors.lastname: Kilama
authors.forename: M
authors.initials: M
authors.lastname: Tanner
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D007963:Leukocytes, Mononuclear / Q000382:microbiology / Q000469:parasitology; D017780:Malaria Vaccines / Q000276:immunology*; D010455:Peptides / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology*; D015995:Prevalence; D013636:Tanzania / Q000453:epidemiology
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D010455:Peptides